Simulations Plus, Inc. (NASDAQ:SLP) Q1 2024 Earnings Conference Call January 3, 2024 5:00 PM ET
Company Participants
Tamara Gonzalez - Investor Relations, Financial Profiles
Shawn O'Connor - Chief Executive Officer
Will Frederick - Chief Financial Officer and Chief Operating Officer
Conference Call Participants
Matt Hewitt - Craig-Hallum Capital Group
David Larsen - BTIG
François Brisebois - Oppenheimer
Operator
Greetings, and welcome to the Simulations Plus First Quarter Fiscal 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
It is now my pleasure to introduce Tamara Gonzalez from Financial Profiles. Thank you. Ms. Gonzalez, you may begin.
Tamara Gonzalez
Welcome to the Simulations Plus first quarter fiscal 2024 financial results conference call.
With me today are Shawn O'Connor, Chief Executive Officer, and Will Frederick, Chief Financial Officer and Chief Operating Officer of Simulations Plus.
Please note that we updated our quarterly earnings presentation, which will serve as a supplement to today's prepared remarks. You can access the presentation on our Investor Relations website at www.simulations-plus.com. After management's commentary, we will open the call for questions.
As a reminder, the information discussed today may include forward-looking statements that involve risks and uncertainties. Words like believe, expect, and anticipate refer to our best estimates as of this call. There can be no assurances that these will actually take place. So, our actual future results could differ significantly from these statements. Further information on the company's risk factors is contained in the company's quarterly and annual reports and filed with the Securities and Exchange Commission.
With that said, I'll turn the call over to Shawn O'Connor. Shawn?
Shawn O'Connor
Thank you, Tamara. Good afternoon, everyone, and thank you for joining our first quarter fiscal 2024 conference call.
Results for the first quarter of fiscal 2024 played out as anticipated. We delivered solid revenue growth of 21% and diluted earnings per share of $0.10, in-line with our guidance for the full year. Our team performed very well in what is still a softer environment for our biotech and pharmaceutical clients.
A few notes on the background behind the results. As our clients closed out their fiscal years, we saw the usual spend before you lose in 2023 activity, a rush to use allocated budgets before the year-end. Even though the spend fell short of previous year-end highs, we were encouraged that it was greater than what we saw last year.